Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2025
vol. 29
 
Share:
Share:
abstract:
Review paper

Small intestinal bacterial overgrowth and intestinal methanogen overgrowth in gastrointestinal malignancies

Aleksandra Mechlińska
1
,
Katarzyna Frąckiewicz
2
,
Katarzyna Gładyś-Cieszyńska
3
,
Dagmara Buczek
1
,
Rafał Dziadziuszko
1

  1. Department of Oncology and Radiotherapy, Medical University of Gdańsk and University Clinical Center, Gdańsk, Poland
  2. Department of Physiopathology, Medical University of Gdańsk, Gdańsk, Poland
  3. Department of Clinical Nutrition, Medical University of Gdańsk, Gdańsk, Poland
Contemp Oncol (Pozn) 2025; 29 (1): 11–21
Online publish date: 2025/03/18
View full text Get citation
 
PlumX metrics:
Small intestinal bacterial overgrowth (SIBO) is defined by an abnormal proliferation of colon-specific bacteria in the small intestine, whereas intestinal methanogen overgrowth (IMO) manifests with an increase of methane-producing archaea, specifically Methanobrevibacter smithii. Both conditions can disrupt gastrointestinal motility and manifest with various clinical symptoms. Small intestinal bacterial overgrowth appears to increase the risk of malnutrition and negatively affect malabsorption of essential nutrients such as vitamin B12 and fat-soluble vitamins. This concern is particularly relevant for cancer patients as malnutrition can adversely affect treatment outcomes and mortality rates. Small intestinal bacterial overgrowth prevalence is 2.5–22% in the general population, with significantly higher rates observed in cancer patients, depending on a study, 65% of gastric and colorectal cancer patients, 63.3% of pancreatic cancer patients compared to 13.3% in healthy controls. Gastrointestinal complications, particularly in cases of gastrointestinal cancers, can arise from both the disease itself and its treatment. Managing symptoms becomes more challenging when SIBO occurs as its symptoms are often ambiguous and overlap with those of other conditions. This review summarizes the current state of knowledge on SIBO and IMO in gastrointestinal cancers. Current knowledge on SIBO and IMO, particularly in gastrointestinal cancer, is limited by the lack of validated diagnostic standards, evidence-based nutritional guidelines, and a focus on symptom control rather than underlying mechanisms. There is a need for research on recurrence despite treatment, as well as studies specifically targeting SIBO and IMO in cancer rather than as comorbidities. Future efforts should prioritize developing reliable diagnostics, understanding recurrence mechanisms, and exploring personalized therapies and nutritional interventions.
keywords:

gastrointestinal cancer, SIBO, IMO, nutrition, breath tests

Quick links
© 2025 Termedia Sp. z o.o.
Developed by Bentus.